Synopsis
Synopsis
0
EU WC
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anexate
2. Flumazepil
3. Lanexat
4. Ro 15 1788
5. Ro 15-1788
6. Ro 151788
7. Romazicon
1. 78755-81-4
2. Anexate
3. Flumazepil
4. Romazicon
5. Lanexat
6. Mazicon
7. Ro 15-1788
8. Fumazenil
9. Flumazenilum [latin]
10. Flumazenilo [spanish]
11. Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4h-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate
12. Flumazenilo
13. Flumazenilum
14. Ro-15-1788
15. [11c]flumazenil
16. Flumazenil (ro 15-1788)
17. Ro 151788
18. Ethyl 8-fluoro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
19. Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
20. Chembl407
21. Nsc-759193
22. Ro15-1788
23. Mls000028850
24. Ro-151788
25. Chebi:5103
26. 4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylic Acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, Ethyl Ester
27. Ethyl 12-fluoro-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,11,13-pentaene-5-carboxylate
28. Ro 15-1788/000
29. Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate
30. 40p7xk9392
31. Ro-1722
32. Ncgc00015439-06
33. Smr000058450
34. Ro-151788000
35. Ro-41-8157
36. Dsstox_cid_3064
37. Ro-15-1788/000
38. Dsstox_rid_76860
39. Dsstox_gsid_23064
40. Flumazil
41. [3h]ro15-1788
42. Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
43. Cas-78755-81-4
44. Sr-01000075879
45. Brn 4763661
46. Flumenazil
47. Flunarizin
48. Roma
49. [11c]flumazenil (pet Ligand)
50. Unii-40p7xk9392
51. Flumazenil [usan:usp:inn:ban]
52. Romazicon (tn)
53. Flumazenil Authentic
54. Fyp
55. Flumazenil- Bio-x
56. Mfcd00242764
57. Tocris-1328
58. Flumazenil [mi]
59. Flumazenil [inn]
60. Flumazenil [jan]
61. Opera_id_1516
62. Flumazenil [usan]
63. Lopac-f-6300
64. Flumazenil [vandf]
65. Biomol-nt_000285
66. Upcmld-dp137
67. Flumazenil [mart.]
68. Ethyl 8-fluoro-5-methyl-5,6-dihydro-6-oxo-4h-imidazo(1,5-a)(1,4)benzodiazepine-3-carboxylate
69. Flumazenil [usp-rs]
70. Flumazenil [who-dd]
71. Lopac0_000506
72. Schembl79030
73. Flumazenil (jan/usp/inn)
74. Mls000759529
75. Mls001076354
76. Mls001424108
77. Bidd:gt0766
78. Bpbio1_001190
79. Gtpl4192
80. Gtpl4367
81. Zinc1464
82. Dtxsid2023064
83. Flumazenil [orange Book]
84. Upcmld-dp137:001
85. Bdbm26263
86. Flumazenil [ep Monograph]
87. Flumazenil [usp Monograph]
88. Hms2051d17
89. Hms2089b15
90. Hms2234f06
91. Hms3261f13
92. Hms3267p09
93. Hms3374e10
94. Hms3393d17
95. Hms3412g20
96. Hms3657k11
97. Hms3676g20
98. Hms3884g11
99. Pharmakon1600-01505701
100. Afc-3002
101. Amy39505
102. Bcp07573
103. Hy-b0009
104. Flumazenil, >99% (hplc), Solid
105. Tox21_110148
106. Tox21_500506
107. Nsc759193
108. Pdsp1_001778
109. Pdsp2_001761
110. S1332
111. Akos015888159
112. Tox21_110148_1
113. Ac-6846
114. Ccg-100968
115. Cs-0629
116. Db01205
117. Lp00506
118. Nc00218
119. Nsc 759193
120. Sdccgsbi-0050490.p003
121. Ncgc00015439-01
122. Ncgc00015439-02
123. Ncgc00015439-03
124. Ncgc00015439-04
125. Ncgc00015439-05
126. Ncgc00015439-07
127. Ncgc00015439-08
128. Ncgc00015439-09
129. Ncgc00015439-11
130. Ncgc00015439-14
131. Ncgc00015439-22
132. Ncgc00025116-01
133. Ncgc00025116-02
134. Ncgc00025116-03
135. Ncgc00025116-04
136. Ncgc00025116-05
137. Ncgc00261191-01
138. As-13923
139. Bf164469
140. Flumazenil 100 Microg/ml In Acetonitrile
141. Sbi-0050490.p002
142. Db-056331
143. Eu-0100506
144. F-145
145. F0958
146. Ft-0630863
147. Sw197598-2
148. C07825
149. D00697
150. F 6300
151. Ab00572626-12
152. Ab00572626-13
153. Ab00572626_14
154. Ab00572626_15
155. 755f814
156. A839484
157. Q421920
158. Q-201122
159. Sr-01000075879-1
160. Sr-01000075879-3
161. Sr-01000075879-7
162. Brd-k98769987-001-01-3
163. Brd-k98769987-001-12-0
164. Z1551429735
165. Flumazenil, United States Pharmacopeia (usp) Reference Standard
166. Ethyl 8-fluoro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate.
167. 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic Acid Ethyl Ester
168. 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic Acid, Ethyl Ester
169. 8-fluoro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic Acid Ethyl Ester
170. Ethyl 12-fluoro-8-methyl-9-oxo-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(14),3,5,10,12-pentaene-5-carboxylate
171. Ethyl 8-fluoranyl-5-methyl-6-oxidanylidene-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
172. Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]-benzodiazepine-3-carboxylate
173. Ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4h-imidazo[1,5-a][1,4]benzodiazepin-3-carboxylate
174. Ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4h-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate #
| Molecular Weight | 303.29 g/mol |
|---|---|
| Molecular Formula | C15H14FN3O3 |
| XLogP3 | 1 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Exact Mass | 303.10191948 g/mol |
| Monoisotopic Mass | 303.10191948 g/mol |
| Topological Polar Surface Area | 64.4 Ų |
| Heavy Atom Count | 22 |
| Formal Charge | 0 |
| Complexity | 461 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Flumazenil |
| PubMed Health | Flumazenil (Injection) |
| Drug Classes | Toxicology-Antidote Agent |
| Drug Label | ROMAZICON (flumazenil) is a benzodiazepine receptor antagonist. Chemically, flumazenil is ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a](1,4) benzodiazepine-3-carboxylate. Flumazenil has an imidazobenzodiazepine structure, a calculated... |
| Active Ingredient | Flumazenil |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 0.5mg/5ml (0.1mg/ml); 1mg/10ml (0.1mg/ml) |
| Market Status | Prescription |
| Company | Hikma Farmaceutica; Sandoz; Fresenius Kabi Usa; Hikma Maple; Sagent Pharms; Bedford Labs; Agila Speclts |
| 2 of 2 | |
|---|---|
| Drug Name | Flumazenil |
| PubMed Health | Flumazenil (Injection) |
| Drug Classes | Toxicology-Antidote Agent |
| Drug Label | ROMAZICON (flumazenil) is a benzodiazepine receptor antagonist. Chemically, flumazenil is ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a](1,4) benzodiazepine-3-carboxylate. Flumazenil has an imidazobenzodiazepine structure, a calculated... |
| Active Ingredient | Flumazenil |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | 0.5mg/5ml (0.1mg/ml); 1mg/10ml (0.1mg/ml) |
| Market Status | Prescription |
| Company | Hikma Farmaceutica; Sandoz; Fresenius Kabi Usa; Hikma Maple; Sagent Pharms; Bedford Labs; Agila Speclts |
For the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate supportive and symptomatic measures.
FDA Label
Flumazenil antagonizes the CNS effects produced by benzodiazepines, but does not antagonize the central nervous system effects of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (including ethanol, barbiturates, or general anesthetics) and does not reverse the effects of opioids.
Antidotes
Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)
GABA Modulators
Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here. (See all compounds classified as GABA Modulators.)
V - Various
V03 - All other therapeutic products
V03A - All other therapeutic products
V03AB - Antidotes
V03AB25 - Flumazenil
Route of Elimination
Flumazenil is completely (99%) metabolized. Elimination of radiolabeled drug is essentially complete within 72 hours, with 90% to 95% of the radioactivity appearing in urine and 5% to 10% in the feces.
Volume of Distribution
0.9 to 1.1 L/kg
Clearance
1 L/hr/kg [healthy volunteers receiving a 5-minute infusion of a total of 1 mg]
Hepatic. Flumazenil is completely (99%) metabolized. The major metabolites of flumazenil identified in urine are the de-ethylated free acid and its glucuronide conjugate.
Initial distribution half-life is 4 to 11 minutes and the terminal half-life is 40 to 80 minutes. Prolongation of the half-life to 1.3 hours in patients with moderate hepatic impairment and 2.4 hours in severely impaired patients. Compared to adults, the elimination half-life in pediatric patients was more variable, averaging 40 minutes (range: 20 to 75 minutes).
Flumazenil, an imidazobenzodiazepine derivative, is a benzodiazepine antagonist. It competitively inhibits the benzodiazepine binding site on the GABA/benzodiazepine receptor complex. Flumazenil is a weak partial agonist in some animal models of activity, but has little or no agonist activity in man.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - 0.5MG/5ML (0....DOSAGE - INJECTABLE;INJECTION - 0.5MG/5ML (0.1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20073
DOSAGE - INJECTABLE;INJECTION - 1MG/10ML (0.1...DOSAGE - INJECTABLE;INJECTION - 1MG/10ML (0.1MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20073
Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Market Place
